Latest Healthcare News

Rhythm Biosciences has announced a $3.75 million placement to accelerate the commercial launch of its ColoSTAT® cancer detection test and expand its geneType™ product suite into key markets. The capital raise includes director participation and attaching options, pending shareholder approval.

Rhythm Biosciences is raising up to $3.75 million through a share placement to fund the launch of its ColoSTAT® colorectal cancer diagnostic and accelerate commercialization of its geneType™ portfolio.

Cleo Diagnostics has launched a health economic study in partnership with EntityRisk and Norstella to support the U.S. market entry of its Ovarian Cancer Pre-Surgical Test, aiming to refine reimbursement strategies and accelerate commercialisation.

Apiam Animal Health has received a non-binding indicative proposal from Adamantem Capital Management to acquire the company at $0.88 per share, sparking a potential shift in ownership for the veterinary services leader.

GWA Group Limited has reported a solid FY25 financial performance with modest revenue and profit growth, alongside a dividend increase and a new $30 million share buyback program.

Lumos Diagnostics has submitted its CLIA waiver application for FebriDx® to the FDA, backed by strong clinical data and triggering significant milestone payments. Approval could expand the U.S. market opportunity fifteen-fold to over $1 billion.

dorsaVi Ltd has raised A$5 million through a strategic placement to accelerate development of its next-generation RRAM-enabled sensors and robotics platforms, signaling a bold expansion into edge AI and neuromorphic computing.

Audeara Limited reports a strong start to FY26 with a 46% revenue increase driven by Australian wholesale growth and a key international partnership. The company’s global ambitions are further highlighted by multiple export award nominations.

WAM Leaders Limited has raised its fully franked full year dividend to 9.4 cents per share despite underperforming the ASX 200 in FY2025, signaling confidence in a market inflection and a strategic pivot towards quality and growth sectors.

WAM Global Limited outperformed the MSCI World Index in FY2025 with a 19.4% portfolio gain, enabling a higher fully franked dividend of 17 cents per share. The company’s strong results reflect strategic investments in undervalued global growth stocks amid volatile markets.

WAM Global Limited reported a robust 39.8% increase in net profit for FY2025, driven by a 19.4% growth in its investment portfolio and declared a fully franked full year dividend of 17 cents per share. The company’s diversified global holdings and disciplined investment approach underpin its strong shareholder returns.

Wellnex Life announces the resignation of joint CEO George Karafotias, with Zack Bozinovski stepping up as sole CEO. The company plans to repay a $705,000 director loan within 90 days.